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Stroke remains a disease with a serious impact on quality of life but few eﬀective treatments exist. There is an urgent need to
develop and/or improve neuroprotective strategies to combat this. Many drugs proven to be neuroprotective in experimental
modelsfailtoimprovepatientoutcomeinaclinicalsetting.Anemergingtreatment,therapeutichypothermia(TH),isapromising
neuroprotective therapy in stroke management. Several studies with TH in experimental models and small clinical trials have
shown beneﬁcial eﬀects. Despite this, implementation into the clinical setting is still lacking due to methodological considerations
as well as hypothermia-related complications. This paper discusses the possible opportunities and limitations of the use of TH in
animal models and the translation into the clinic.
1.Introduction
Stroke is the third leading cause of death in industrialized
countries, after cardiovascular diseases and cancer, and is the
main cause of severe and long-term disability. Moreover, as
our society ages, the incidence of stroke will increase and will
becomeaconsiderablesocioeconomicburdenonsocietydue
to the excessive costs of long hospitalisations, nursing care,
and rehabilitation [1–5].
So far, two major strategies in the treatment of throm-
botic stroke exist: thrombolysis and neuroprotective ther-
apies. Thrombolysis (or recanalization) with recombinant
tissue plasminogen activator (rt-PA) is the only approved
and eﬀective therapy after thrombotic stroke thus far. Unfor-
tunately, treatment with rt-PA has important limitations
such as a short treatment window (3-4.5h), reperfusion-
associated injury, and hemorrhagic complications. Conse-
quently, less than 10% of all patients with stroke can be
treated with thrombolytic agents [1–4, 6–8]. Although other
agents including platelet inhibitors (aspirin), anticoagulants
(ancrod, heparins), and prourokinase have been used in
the management of acute stroke, there is only poor or no
evidence that these approaches improve outcome [4, 9, 10].
Alternatively, neuroprotection after an acute ischemic stroke
antagonizes, interrupts, reduces, or slows down injurious
biochemical and molecular events [11]. Neuroprotective
strategies mostly focus on reducing damage in the penumbra
and thus improving the outcome after stroke [12]. Some
neuroprotective agents have shown promising results in
animal studies; however, very few clinical trials show the
same neuroprotective eﬀect in patients with an ischemic
stroke [13–15].
Therapeutic hypothermia (TH) is one of the best studied
neuroprotective therapies. Small decreases in brain temper-
ature are well tolerated and have been shown to confer a
signiﬁcant degree of neuroprotection in several animal mod-
e l so fc e r e b r a li s c h e m i aa sw e l la sar e d u c t i o no ft h ee x t e n t
of ischemic brain damage and improvement of neurological
function [16–21]. Clinical trials and experimental studies in
acute stroke indicate that there is an association between
body temperature, initial stroke severity, infarct volume, and
clinical outcome [22–24]. Increased brain temperature is2 Stroke Research and Treatment
associated with deleterious eﬀects on injured brain tissue
[24].Fever,evenamildone,duringtheﬁrstfewdaysofacute
strokeisassociatedwithaworseclinicaloutcome[22,24,25].
This is a concern as twenty-ﬁve percent of stroke patients
have a body temperature of 37.5◦C or more within the ﬁrst
6 hours after the onset of the symptoms [6]. In contrast,
clinical observations have revealed that patients whose
body temperature was low at admission to hospital have a
better neurological outcome than patients with normal or
high body temperature [25]. In addition, controlling body
temperature below 36.5◦C has proven to correlate with good
clinical outcome [26]. Therefore, the conclusion can be
drawn that increases in brain temperature escalate neuronal
damage whereas lowering the brain temperature reduces
braindamage[5].Thus,althoughafeverisconsideredtobea
normalphysiologicaldefensiveresponsetoinfection,inﬂam-
mation, and several other conditions, avoiding hyperthermia
and controlling the body temperature are necessary to
prevent a worse outcome after cerebral ischemia [19, 27, 28].
Understanding the ischemic cascade, including excito-
toxicity, free radical production, and inﬂammatory and
apoptotic pathways, is mandatory in order to develop new
therapeutic strategies for stroke. Several extensive reviews
on the complex ischemic cascade after stroke have been
published [2, 3, 25, 29–32]. Brieﬂy, when a brain vessel is
occluded, a series of cellular and molecular events occur,
starting with a decrease in cerebral blood ﬂow which can
interfere with ion homeostasis. Indeed, within minutes to a
few hours, the occlusion leads to increased intracellular cal-
cium levels and glutamate release, causing excitotoxicity and
aspreadingdepressionthroughouttheischemicregion.Cells
start to depolarize, causing even more calcium inﬂux and
glutamate release. Additionally, water will passively follow
theioninﬂux,resultingincytotoxicedema[1,31,33].Aftera
few hours to a few days, the high intracellular calcium levels
lead to an overactivation of several proteolytic enzyme sys-
tems that degrade cytoskeletal proteins. Activation of Ca2+-
dependent enzymes, including phospholipase A2,c y c l o o x y -
genase, and neuronal nitric oxide synthase results in addi-
tional cellular damage and the generation of reactive oxygen
species (ROS), which subsequently damage membranes,
mitochondria, and DNA. As a result of all these stimulatory
inﬂuences, an apoptotic and neuroinﬂammatory response
develops [3, 29–31, 34]. Repair and regeneration over the
following months will determine the ultimate damage [35].
In all cases, the location of the original occlusion, and
whether the occlusion was permanent or transient, is critical
in determining the size and severity of the insult [25, 36].
TH protects the brain in various ways. Among these,
it retards energy depletion by lowering the metabolic and
the enzymatic rate, restores the neurotransmitter balance,
reduces the intracellular calcium inﬂux, reduces intracellular
acidosis, suppresses the generation of ROS, suppresses
inﬁltration of inﬂammatory cells, prevents blood-brain
barrier disruption, suppresses speciﬁc cell death pathways,
or upregulates cell survival mechanisms [17, 23, 34, 37, 38].
A review of the mechanisms of action of hypothermia was
not in the scope of this manuscript. Therefore, the reader is
referred to a number of reviews on this subject [17, 23].
2. ExperimentalStudies
Several experimental stroke models have been developed
over the last decade to mimic human stroke. Of these,
occlusion of the middle cerebral artery (MCA) is the closest
to the patient’s situation. Several strategies have been used
to induce focal cerebral ischemia near the MCA including
the embolic model, the intraluminal suture MCA occlusion
model, the photothrombosis model, and the endothelin-1
model. These models are well described by Durukan and
Tatlisumak [3] .T h ec e r e b r a li n s u l ti ns t r o k em o d e l sm a y
vary from permanent to transient occlusions and transient
models are diverse in the occlusion time, varying from 30
m i n u t e st o3h o u r s[ 23]. Due to the range of model variables,
the severity of functional and structural outcome changes
depend on the exact experimental protocol, and thus it is
important to emphasise which experimental model is used
[39].
In stroke models, diﬀerent types of animals are used,
including rats, mice, rabbits, and gerbils. The rat is most
commonly used in experimental studies for several reasons
including the resemblance between human and rat cere-
brovascular anatomy and physiology, the moderate size of
the animal which allows easy monitoring of physiological
parametersaswellascytologicalanalysisofthebrain,andthe
relative homogeneity within strains [3]. Mice are preferred
when genetic modiﬁcations to investigate speciﬁc diﬀerences
in the pathophysiology and ischemic cascade of stroke are
required. Transgenic mice oﬀer the advantage of a short
gestation time (18.5–21 days) and perhaps most importantly
a well-developed set of technologies for introducing genetic
modiﬁcations [40].
While experimental stroke models are an important tool
to identify new treatment strategies, there are a few impor-
tant pitfalls. There is not “one” ideal ischemic stroke model
since human stroke itself is a diverse condition [3]. Each
model only mimics some aspects of the pathophysiology
and the progression of the human stroke. Furthermore, the
species and the strain that are used, even within the same
laboratory, may determine the outcome of a treatment strat-
egy. Portelli et al. [41] found that several pharmacological,
behavioural, and neurochemical factors were signiﬁcantly
diﬀerent from one breeding location to another and could
even vary in time between rats coming from the same
breeding location. So, it is likely that genetic diﬀerences
have an eﬀect on infarct outcomes in the various stroke
models. Ren et al. [42] demonstrated signiﬁcant diﬀerences
in temporal window for hypothermic protection among rats
from diﬀerent strains in which MCA occlusion was induced.
Furthermore, even if the same model is used, technical
manipulations can vary between investigators of diﬀerent
laboratories. The location and the intensity of the lesion as
well as its progression can vary accordingly [42].
Currently, experiments are generally performed in young
healthyrodents. This is in contrastwiththe clinical situation,
where most patients are elderly and have concomitant
pathologies which can aﬀect the outcome of an ischemic
incident. Hyperglycemia, for example, plays a role in the
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cerebral damage and increased morbidity and mortality in
acute ischemic stroke [43, 44]. It is important to take these
risk factors and comorbidities into account when testing on
animals. Experiments performed in aged rodents suﬀering
from hypertension, hypercholesterolemia, and/or diabetes
arethereforemorerelevanttoclinicalpractice[45,46].These
conditions were formulated in the original Stroke Therapy
Academic Industry Roundtable (STAIR) criteria [47].
Technicalcomplicationsalsocompromisetheaccuracyof
animal stroke models. While brain temperature is the critical
issue in regard to neuroprotection in stroke, most exper-
imental studies rely on core temperature measurements,
which are usually estimated by sampling rectal temperature
because it is easy and inexpensive [45]. A few researchers
have used telemetry probes to measure temperature, most
often in the core but also in the brain [48, 49]. Although
some authors claimed that rectal temperature can nicely
predict brain temperature, there is conﬂicting data about
this correlation [18, 49]. One study in rodents showed
that the core temperature is about 0.7◦C higher than brain
temperature [49] whereas another study in rodents found
that brain temperature was 0.2 to 0.7◦C higher than rectal
temperature [18]. Since the temperature is not consistent
throughout the body or brain, there is no consensus in
which brain region measurements should be performed.
Not only the brain region is important, but there is also
ad i ﬀerence in temperature between the ischemic and the
contralateral hemisphere. Even the way TH is induced could
even inﬂuence the correlation between the core and brain
temperature. Measuring the temperature in freely moving
animals or animals under anaesthesia may be an important
consideration. As minimal changes in brain temperature
c a nh a v ep r o t e c t i v ee ﬀects, standard methods of measuring
temperature should be elaborated to allow comparison
between diﬀerent studies.
Knowing the optimal depth of hypothermia is important
for clinical studies because of the increasing side eﬀects
associated with increased temperature reduction. Depending
on the depth of cooling, TH has been classiﬁed in diﬀerent
levels: minimal (35◦C), mild (32–34◦C), moderate (28–
32◦C), deep (20–28◦C), profound (5–20◦C), and ultrapro-
found (<5◦C) [17]. From the literature, it is not clear which
is the most appropriate target temperature, but mild and
moderate hypothermia have been shown to be protective
in animal models and cause fewer side eﬀects than deep
hypothermia [18, 20, 50]. An animal study comparing mild
andmoderateTHshowedthat33◦Cwasbettertoleratedthan
30◦C in a rat model of transient focal cerebral ischemia [18].
Another study showed that treatment with hypothermia
of 33-34◦C in the reperfusion period of focal cerebral
ischemia is superior to all other applied temperatures [51].
A third study showed that postischemic hypothermia of
32◦C produced a larger reduction in infarct volume than
27◦C[ 52]. Therefore, it seems that mild TH is superior to
moderate TH.
Animportantobservationisthatinmanyanimalstudies,
TH is initiated before or at the onset of the insult. However,
this is in contrast with the clinical situation, where most
patients reach the hospital several hours after symptom
onset. Consequently, neuroprotective agents targeting early
events in the ischemic cascade are unrealistic, especially
because at that time a signiﬁcant amount of cerebral
tissue is already impaired [1]. Animal research suggests
that intraischemic hypothermia is more eﬀective than
postischemic hypothermia [23]. However, to better mimic
clinical settings, initiation of the TH should be delayed
in experimental settings and the optimal time window for
inducing hypothermia should be determined. Recently, we
showed [53] that in the endothelin-1 rat model, a 2-hour
mild hypothermia treatment delayed by 1 hour after the
insult is still neuroprotective and improves neurological
outcome whereas a delay of 2 hours was ineﬀective. In other
MCA occlusion models, similar results have been reported.
For instance, Maier et al. [54] showed that 2 hours of
hypothermia reduced the infarct volume, even when delayed
up to 90 minutes after a 2-hour MCA occlusion. A study
by Ohta et al. [55] showed that the hypothermic treatment
could be delayed up to 4 hours after 2 hours MCA occlusion
if cooling was prolonged for 48 hours. So it seems that
hypothermia is neuroprotective when applied early after the
insult and remains beneﬁcial, if the duration of the cooling is
prolonged.
Most patients, in clinical trials, receive the hypothermic
treatment for several days (1 to 3 days) [56]. However, this is
in contrast with most experimental studies, where animals
mostly receive short periods of cooling (few hours). A rat
study showed that a mild hypothermic treatment (using core
temperature telemetry measurements) of 48 hours provided
superior protection compared to a hypothermic treatment
of 12 hours [48]. Another study showed that 22 hours of
mild hypothermia (using rectal temperature measurements)
was superior to a 3-hour treatment [57]. These data suggest
that short periods of cooling may lead to transient neuropro-
tection.Therefore,prolonginghypothermiatreatmentmight
provide permanent neuroprotective eﬀects. As most patients
reach the hospital several hours after the cerebral insult, it
is possible that longer treatment durations may be necessary
when the initiation of cooling is delayed.
Therewarmingphaseafterhypothermictreatmentisalso
important as rapid rewarming may lead to rebound phe-
nomena and enhanced deleterious ischemic eﬀects. Berger
et al. [58] compared fast rewarming (within 20 minutes)
with slow rewarming (within 2 hours) and showed that
slow rewarming signiﬁcantly reduced the infarct volume
compared to fast rewarming. Therefore, as the rewarming
phase plays a crucial role in inﬂuencing the outcome after
stroke, it is important that the rewarming phase should
be studied in experimental studies as well or at least be
elaborated upon in the experimental protocol to allow
comparison.
Most animals are sacriﬁced within a few days after
ischemic onset preventing the study of long-term events [45,
46, 59]. However, because complex processes of the ischemic
cascade can last up to some months after the ischemic insult,
it is desirable to monitor the animals for a longer period of
time than is currently used.
Currently, most experiments are carried out on male
animals only, but researchers should consider the possibility4 Stroke Research and Treatment
that the sex and the hormone changes might inﬂuence stroke
outcome. Suzuki et al. [60] showed that estrogens protect the
brain against stroke injury which points to an urgent need
for studies comparing males and females, and the hormonal
changes with it. Besides sex hormones, poor outcome was
also associated with high levels of stress hormones. Studies
in rodents showed that stress delays or diminishes recovery
of cognitive functions after cerebral ischemia [61].
Another important issue to be addressed is the anaes-
thetic used in experimental studies. Studies using TH are
carried out on anesthetized animals to avoid shivering.
However, the choice of the anaesthetic can inﬂuence the
clinical outcome [62] and therefore, the use of a sham
group is mandatory. Furthermore, as the method of cooling
depends on the choice of the anaesthetic (such as phar-
maceuticals and inhalation anaesthetics), it is important to
stress these experimental conditions as well. An important
contrast between experimental research and the clinical
situation is the use of sedation and ventilation. In the
clinical setting, the use of anaesthetics has decreased the
last few years because of the potential side eﬀects [22].
While in animal models, most studies are still carried out
on anesthetized animals when cooling techniques are used.
Animals are mostly cooled via surface cooling techniques,
such as with fans, water or alcohol spray, use of a cold room,
or administration of some chemicals. Selectively cooling
the brain, for example with an extracranial cooling coil, is
becoming more popular in experimental rat models [63].
In the clinical situation, however, surface cooling combined
with endovascular cooling is commonly used [26, 27, 37, 38,
64, 65].
A selection of outcome parameters should be used when
evaluatingtheneuroprotectiveeﬀectofTHinanimalstudies.
While histological endpoints are important for demonstrat-
ing reductions in infarct volume, these assessments may
not necessarily be associated with improved functional and
neurological outcome [45]. Several laboratories have consis-
tently shown that TH reduces both the extent of neurological
damage and improves neurological function [37]. However,
simple measurements of recovery are not suﬃcient to detect
improvements in neurological function, as they do not
reﬂect the complexity of functional impairment and may not
accuratelypredictneuroprotection[45].Functionaloutcome
should be tested with several sensorimotor behavioural and
cognitive tests, such as limb placing, beam walking, grid
walking, rotarod, sticky label test, staircase test, and Morris
water maze [3, 66]. Subsequently, combined functional
and histological endpoints are necessary for examining the
protective eﬀect of hypothermia or drugs in stroke models
[67].
Physiological parameters are strictly controlled during
experimental studies, which is in contrast with the clinical
setting. It is possible that neuroprotective agents convey a
beneﬁcialeﬀectinanimalmodelsbecausesomephysiological
parameters (such as the body temperature, blood pressure,
etc.) are controlled in animal experiments. Clinical evidence
suggests that admission of acute stroke patients to a stroke
unit with intensive monitoring can lead to improved out-
come [68]. Optimal medical care is important to reduce
the risk of complications and to stabilize a number of
acute physiological parameters that may worsen ischemia,
such as high or low blood pressure, ﬂuid and electrolyte
management, hypoxemia, body temperature, infections, and
blood glucose [12]. A strict control of the physiological
parameters in stroke patients should improve the outcome.
In summary, a suitable experimental animal model
should meet the following criteria: it should be reliable,
minimally invasive, and yield reproducible lesions with
minimum variability. Ageandcomorbidities shouldbetaken
into account before conducting an experimental study. The
physiological variables should also be monitored and main-
tained within normal ranges [3]. Not only the acute eﬀects
of TH, but also the long-term eﬀects should be studied. The
model has to be relevant to human stroke and consider all
the above-mentioned impediments when these experiments
aretranslatedintoclinicalsettings.Althoughfurtherresearch
is needed to investigate the optimal conditions for TH, the
current knowledge suggests that TH should be initiated as
soon as possible, and if the treatment is delayed longer,
cooling should be considered. Several studies also suggest
that mild hypothermia is neuroprotective and produces
fewer complications than deep cooling. As the rewarming
phase strongly inﬂuences the outcome after stroke, it is
crucial that all studies use slow rewarming phases.
3.ClinicalStudies
There is an urgent need to improve the translation of
preclinical research into the clinic. To help the translation
of animal studies to human clinical trials, the STAIR criteria
were set up to improve the understanding of experimental
data and extrapolation to a clinical setting. The STAIR
provides recommendations for clinical development of acute
stroke therapies, including elimination randomization bias,
calculation of sample size, speciﬁcation of the inclusion and
exclusion criteria, blind assessment of the outcome, use of
multiple species, and reporting animals excluded from the
analysis [1, 47].
As the ischemic cascade is so complex, it is possible that
diﬀerent types of stroke (ischemic or hemorrhagic) beneﬁt
from diﬀerent therapeutic protocols [1]. When running a
clinical trial, patients with the same stroke severity should
beenrolled,inordertoproducecomparableresults.Ofthese,
patientswhohavehadanearlierstrokeorothercomorbidity,
should be placed in a subgroup during the analysis as it
might inﬂuence the outcome [11]. Before including patients
in a clinical trial, inclusion and exclusion criteria should
be well deﬁned and optimized. The protocol has to include
cutoﬀ points for the National Institute of Health Stroke
Scale (NIHSS) and the Barthel index and should have clear
outcome measurements. As hypothermia is less eﬀective in
ischemia without reperfusion, any neuroprotective strategy
should, if possible, be combined with recanalization therapy.
A number of small clinical trials of hypothermia have
already been performed in stroke patients (Table 1), such as
the “Copenhagen Stroke Study” [70], the “Cooling for Acute
Ischemic Brain Damage” (COOL AID) study [73], and the
“Intravascular Cooling in the Treatment of Stroke-LongerStroke Research and Treatment 5
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tPA Window” (ICTuS-L) study [75]. The “Copenhagen
Stroke Study” showed that modest hypothermia (35.5◦C)
by surface cooling can be achieved in conscious patients
followinganacutestroke[70].TheCOOLAIDstudyshowed
that endovascular cooling (33◦C) is feasible in conscious
patients with moderate to severe ischemic stroke [73]. The
ICTuS-L study showed that endovascular cooling (33◦C)
can be combined with standard thrombolytic therapy [75].
However, further research with larger patient groups is
necessary to evaluate the eﬃcacy of hypothermia after
ischemic stroke as recent studies were not able to show
reduced mortality after an insult [22, 56, 69–75].
Early initiation of hypothermia after stroke gives the
best outcomes, but if hypothermia is delayed, longer cooling
times may also be protective [38, 76] and thus, as most
stroke patients reach the hospital several hours after the
insult, many trials use long therapeutic windows compared
to animal studies (see Table 1). Although a long cooling time
seems attractive, it may increase the risk of complications
[17, 37, 76]. Prolonged hypothermia not only increases the
risk for side eﬀects, it also has an inﬂuence on every organ
system [59].
Although several small clinical trials show that TH
could be safe for stroke patients, there are still a number
of complications that need to be overcome [22, 56, 69].
The most common complications related to hypothermia
are pneumonia, hypovolemia, arrhythmias, hyperglycemia,
bradycardia, thrombocytopenia, hypertension, hypotension,
increased intracranial pressure, electrolyte abnormalities like
hypokalemia, and metabolic acidosis [16, 27]. There are also
complications related to fast rewarming, such as intracranial
hypertension [27].
Asmentionedabove,besidesthecontrolofthebodytem-
perature, it is also important to control other physiological
parameters such as blood glucose, blood pressure, ﬂuid and
electrolyte management, hypoxemia, cardiac arrhythmias,
andinfections[12].Clinicalevidencesuggeststhatadmission
of acute stroke patients to a stroke unit with intensive
monitoring can improve the outcome [68]. Most studies
agree that it is diﬃcult to keep all of the metabolic and
physiologic variables that might inﬂuence the outcome
constant across diﬀerent centers [27]. However, this should
be their goal in order to reduce the risk of a bad outcome and
the risk of complications in stroke patients. Blood markers,
such as NSE and S100β, should also be included, as they can
give an indication of the prognosis and the outcome after
stroke.
TH seems a very promising treatment for stroke if
investigators can reduce the complications related to the
treatment, but there are also other limitations. Endovascular
cooling compared to surface cooling may be better to control
the body temperature more precisely but it is more invasive
[22]. Patients treated with TH have to be admitted to an
intensive care unit, this may generate practical and logistical
problems [46].
Finally, the lack of translation of experimental studies
into human clinical trials reﬂects the lack of resources as well
as shortage of sponsoring from companies and governments
[46, 67]. There is an urgent need for larger clinical trials with
as u ﬃcient number of patients, which might reveal small
but signiﬁcant diﬀerences in outcome and low-incidence
complications [22]. Despite all limitations, researchers still
believe that TH could become the standard therapy in
stroke management, as it already showed promising results
in cardiac arrest patients [22, 50, 77].
4. Conclusion
As only a small percentage of stroke patients can be
treated with thrombolytic agents, there is an urgent need
to develop and to improve neuroprotection strategies. TH
seems to be the most promising neuroprotective therapy in
experimental models with encouraging results in the clinical
setting. The current knowledge from both experimental and
clinical research suggests that TH should be initiated as
soon as possible after stroke onset in order to achieve the
best outcome. Prolonged cooling should be considered if
the initiation of the hypothermia treatment is delayed. As
the rewarming phase strongly inﬂuences the outcome after
stroke,itiscrucialthatallstudiesuseslowrewarmingphases.
Currently, it can be considered that mild hypothermia is
neuroprotective and produces less complications than deep
cooling. At the same time, controlling physiological parame-
ters and the temperature during the hypothermic treatment
are essential for successful clinical or experimental trials.
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